CAPCOM
29.8.2024 14:01:29 CEST | Business Wire | Press release
Capcom Co., Ltd. (TOKYO:9697) today announced that the company will sponsor the Osaka Healthcare Pavilion, which is being exhibited by the Expo 2025, Osaka Pavilion Promotion Committee at Expo 2025, Osaka, Kansai, Japan (Expo 2025, below). Further, the company announced that it will exhibit an interactive experience dubbed Monster Hunter Bridge at the Pavilion in the XD Hall, where visitors can experience the future of entertainment.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240829488620/en/
Monster Hunter Bridge key art (Graphic: Business Wire)
The theme of the upcoming Expo 2025 is “Designing Future Society for Our Lives.” Inspired by the “REBORN” theme of the Osaka Healthcare Pavilion, Capcom decided to exhibit an interactive attraction that incorporates the concept of nature, living things, and the wonder of life, which are important themes in the Monster Hunter series.
Exhibit Details
Monster Hunter Bridge is a wholly-unique attraction that Capcom created exclusively for Expo 2025. Visitors to the hall will don specialized AR devices and be able to enjoy this interactive attraction that weaves together a 360-degree theater, immersive audio, and vibrating floor. Capcom is developing Monster Hunter Bridge with the aim of blending dreams with reality to provide an immersive experience like never before. The company hopes that visitors look forward to this one-of-a-kind Monster Hunter attraction that will bring them up close with Felyne as well as incredible monster encounters, and can only be experienced at Expo 2025.
Facilities Details
The attraction will be housed in a cylinder-shaped theater within the XD Hall that will measure approximately 12 meters in diameter and 5 meters in height and will be created as part of the Osaka Healthcare Pavilion. Capcom will exhibit Monster Hunter Bridge there by creating a space inside the XD Hall that projects the world of Monster Hunter in 360 degrees, utilizing transparent LED displays on the internal walls and ceiling and projectors on the floor. The company developed new specialized AR devices for visitors that feature 105 degrees of visibility in order to create Expo 2025’s most engaging experience. In addition, the company will enhance the immersion of the space by outfitting it with a multitude of speakers set behind the transparent LED displays, wrapping visitors in 360 degrees of sound while vibrations from the floor are synchronized with the on-screen action.
The company is creating these facilities with the cooperation of partner companies exclusively for Monster Hunter Bridge.
Promotional Ticket Campaign
With the desire to contribute to the development and promotion of Expo 2025, which is being held where Capcom was founded, the company will carry out an Expo 2025 “super-advanced one-day pass” double ticket promotional campaign in which it will give away a total of 80,890 tickets to Expo 2025. The promotion is available to everyone who registers for Capcom ID, a unified account with which users can conveniently manage various Capcom games and web services. The company encourages people to refer to the promotional ticket campaign website for more details.
*Only residents of Japan are eligible to participate in the round one entry period. Please refer to the promotional ticket campaign website regarding eligibility for future campaign entry periods.
Capcom is currently developing Monster Hunter Bridge with the aim of providing a special entertainment experience where dreams and reality become one. The company hopes to create the absolute best content at the event and bring success to the Expo 2025, Osaka Pavilion Promotion Committee.
ABOUT the Monster Hunter series:
The Monster Hunter series consists of hunting action games that pit players against giant monsters in beautiful natural environments. After the series created a social phenomenon through play on handheld consoles and solidified its standing as one of Japan’s most beloved game series, it went on to global-brand status with the release of Monster Hunter: World in 2018. With cumulative sales of the series now exceeding 100 million units, Monster Hunter has grown into a global phenomenon.
[Exhibit Details]
1. Name |
Monster Hunter Bridge |
2. Location |
XD Hall, Osaka Healthcare Pavilion, Expo 2025, Osaka, Kansai |
3. Term |
April 13, 2025 - October 13, 2025 |
4. Admission |
Free* |
5. Official Website |
|
6. Ticket Promotion Website |
|
*Entry to this attraction will be by reservation only. Details will be provided at a later date. |
|
*A separate ticket must be purchased to enter Expo 2025, Osaka, Kansai. |
|
ABOUT CAPCOM
Capcom is a leading worldwide developer, publisher and distributor of interactive entertainment for game consoles, PCs, handheld and wireless devices. Founded in 1983, the company has created hundreds of games, including groundbreaking franchises Resident Evil™, Monster Hunter™, Street Fighter™, Mega Man™, Devil May Cry™ and Ace Attorney™. Capcom maintains operations in the U.S., U.K., Germany, France, Hong Kong, Taiwan, Singapore and Tokyo, with corporate headquarters located in Osaka, Japan. More information about Capcom can be found at https://www.capcom.co.jp/ir/english/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240829488620/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 22:42:00 CET | Press release
- Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) is the first systemic treatment for adult patients with advanced SCAC in Europe- The EC approval is based on results of the POD1UM-303 study which showed that adult patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment compared to chemotherapy alone.1 Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meur
Dfns Launches Payouts6.3.2026 21:27:00 CET | Press release
Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i
Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 20:23:00 CET | Press release
Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up
Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 18:30:00 CET | Press release
Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different
Sutherland Launches FinAI Hub to Industrialize Agentic AI for Banking and Financial Services6.3.2026 14:00:00 CET | Press release
A domain-trained AI agent workforce enables production-scale AI across regulated financial institution operations Today, Sutherland announced the launch of Sutherland FinAI Hub, an enterprise Agentic AI platform built exclusively for Banking and Financial Services. As financial institutions accelerate AI adoption, many initiatives remain confined to pilots, unable to scale across legacy systems and core operations. Sutherland FinAI Hub is designed to help close that gap. FinAI Hub is an innovation ecosystem where Sutherland works with clients to design, prototype, and scale Agentic AI workflows across core operations. At launch, the platform brings together a large and expanding workforce of domain-trained AI agents purpose-built for financial institutions, supporting functions across retail banking, payments, cards, consumer and commercial lending, servicing, back office, risk and compliance functions. These modular agents can operate independently or be orchestrated across end-to-end
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom